AbbVie Inc. on Wednesday said it would repurchase $5 billion in shares from Morgan Stanley, following the completion of its Pharmacyclics Inc. acquisition.

In March, the Chicago pharmaceutical company unveiled plans to buy blood cancer-focused Pharmacyclics for about $21 billion--a deal it completed Tuesday. AbbVie had said it would execute an accelerated share-repurchase program to buy back at least half of the equity issued in the transaction promptly after the closing. The company in March lifted its share-repurchase authorization to $10 billion from $5 billion.

Morgan Stanley is expected to make an initial delivery of 68 million shares Wednesday.

Earlier this month, AbbVie sold $16.7 billion in new bonds to help finance the Pharmacyclics deal, marking one of the largest corporate bond deals of the year.

Write to Lisa Beilfuss at lisa.beilfuss@wsj.com

Access Investor Kit for Morgan Stanley

Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=US6174464486

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

AbbVie (NYSE:ABBV)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more AbbVie Charts.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more AbbVie Charts.